Wörwag Pharma: Clinical Bioavailability Study Published

Reading time 1 minutes
Share

Boeblingen, March 2026 - Wörwag Pharma is pleased to announce the publication of its proprietary clinical study in the peer-reviewed journal Food & Nutrition Research. The investigation focuses on optimizing the bioavailability of milk thistle extract and underscores the company’s scientific commitment to the development of advanced formulations.

The human clinical trial was conducted in collaboration with BioTeSys GmbH in Esslingen, Germany. In a randomized, cross-over study involving 18 healthy adults, researchers investigated how different formulation approaches affect the absorption of silybin - the central component of milk thistle extract. The study compared two formulations containing identical amounts of the extract over a 24-hour period.


The published data demonstrate a significantly enhanced absorption of silybin, reaching 8.6 fold higher levels ,using the combination of silymarin with krill oilcompared to a standard formulation. In addition, the formula contains the nutritionally important omega-3 fatty acids and choline. By publishing these results, Wörwag Pharma contributes to pharmacological research and expands the scientific evidence base regarding bioavailability-optimized silymarin formulations.  


"The publication in a recognized scientific journal is a consistent step in our strategy to drive the development of our preparations on a solid scientific foundation," the company stated.

 

Publication Reference:

Engelhart-Jentzsch, K., Gantenbein, A.-K., Schön, C., Wilhelm, M., Stadelmayer, L., Pross, L., Kaiser-Zimmermann, T., Guerrero, G., Jaghutriz, B. A., & Reule, C. (2026). Enhanced bioavailability of a krill oil-based milk thistle extract formulation: in vitro and human studies. Food & Nutrition Research, 70.

https://doi.org/10.29219/fnr.v70.13256